Infliximab for Injection
Efficacy and safety are equivalent to the original drug (Johnson & Johnson/Merck & Co.
The first infliximab biosimilar marketed in China
Infliximab for Injection (Reminton), a recombinant anti-TNF-alpha chimeric monoclonal antibody, was approved for marketing by the National Medical Products Administration (NMPA) on July 14, 2021. It is the first infliximab biosimilar marketed in China. Taking advantage of CHO cell expression system, Remin_x005f ton has been proved with good efficacy, better safety, and lower immunogenicity in clinical studies.
Indications:
Crohn's disease in adults and children over 6 years of age, stulizing Crohn's disease,
ulcerative colitis in adults, ankylosing spondylitis, rheumatoid arthritis, and psoriasis.
Recommended reading
Related products
-
The Latest 5-in-1 Car Jump Starter and Tire Inflator
Contact UsThis innovative device combines four essential functions in one compact unit, ensuring you’re well-equipped for any roadside emergency or outdoor adventure.
-
Jinko Tiger Neo N Type Solar Panel 605W 615W 625W
Contact UsModel NO:78HL4-BDV 605-625 Watt
Cell Type: N-type Mono-crystalline
Weight:34.6 kg
Transport Package:Wooden Pallet and Carton Packing
Specification:2465*1134*30mm
Trademark:Jinko solar
Origin:China -
Deye SUN-8K-G06P3-EU-AM2-P1
Contact Us2 MPP trackers, Max.effciency up to 98.5%
Zero export application,VSG application
String intelligent monitoring (optional)
Wide output voltage range
Anti-PlD function (Optional)






Reviews
There are no reviews yet.